The Pharmaceutical Research and Manufacturers of America (PhRMA) has adopted measures to strengthen its Guiding Principles on Direct to Consumer Advertisements about Prescription Medicines. The group said it intended to affirm its commitment to responsible direct-to-consumer advertising that benefits public health. However, the reaction from Democratic party legislators who control Congress was less than enthusiastic, with one claiming that thePhRMA had merely reworded some its previous positions and ignores the issue of a moratorium on promoting new agents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze